Carlsmed's Q1 2026: Surgeon Adoption, Revenue Surge, & Clinical Wins

Carlsmeds Q1 2026 earnings report is impressive, with a 58% revenue increase to $16.1 million, driven by surgeon adoption and procedures. Their surgeon user base surged by 60% YoY, with strong uptake in lumbar and cervical spine fusions. Production lead times were cut by 30% to 6 business days, boosting gross margins to 77.1%. Peer-reviewed data shows a 74% drop in revision rates for their Aprivo lumbar procedures. Surgeons and hospitals are embracing their surgeon-led growth model, praising workflow integration and better outcomes. Operating expenses rose due to sales and R&D ramps, but cash remains strong at $97.1 million. They raised full-year guidance to $72-77 million, with potential premium reimbursements from CMS. Cervical plating launches are upcoming, indicating rapid growth in personalized spine surgery. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/52280c14d489e4f3